EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost‐effectiveness analysis

Dai Lian, Yuling Gan, Dunming Xiao, Dennis Xuan, Yingyao Chen, Yi Yang iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Dai Lian und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Antineoplastic Combined Chemotherapy Protocols, Nasopharyngeal Carcinoma, Quality-Adjusted Life Years. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Toripalimab, combined with gemcitabine and cisplatin, has been approved as the first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM‐NPC), representing a significant milestone as the first FDA‐approved innovative therapy for this condition. Despite this achievement, there's a lack of data on the cost‐effectiveness of toripalimab for RM‐NPC patients in the American context.

Methods

To assess the cost‐effectiveness of toripalimab plus chemotherapy versus chemotherapy alone, a 3‐state partitioned survival model was constructed. The study involved participants with characteristics matching those in the JUPITER‐02 trial. Cost and utility inputs were collected from literature. Main outcomes measured were quality‐adjusted life year (QALY), and incremental cost‐effectiveness ratio (ICER). Univariate and probabilistic sensitivity analyses, subgroup analyses, and scenario analyses were conducted to verify the robustness of results.

Results

The study found that the toripalimab regimen resulted in 4.390 QALYs at a cost of $361,813, while the chemotherapy‐only regimen yielded 1.685 QALYs at a cost of $161,632. This translates to an ICER of $74,004/QALY, below the willingness‐to‐pay threshold of $150,000/QALY. Sensitivity analyses indicated that utility values, discount rate, and the price of toripalimab significantly impact INMB. With an 87.10% probability of being cost‐effective at a $150,000/QALY threshold, the probabilistic sensitivity analysis supports toripalimab plus chemotherapy as a viable option. Scenario analysis showed that toripalimab remains cost‐effective unless its price increases by 125%. Additionally, a simulated 15‐year study period increases the ICER to $88,026/QALY. Subgroup analysis revealed ICERs of $76,538/QALY for PD‐L1 positive and $70,158/QALY for PD‐L1 negative groups.

Conclusions

Toripalimab in combination with chemotherapy is likely to be a cost‐effective alternative to standard chemotherapy for American patients with RM‐NPC. This evidence can guide clinical and reimbursement decision‐making in treating RM‐NPC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisAntineoplastic Combined Chemotherapy ProtocolsNasopharyngeal CarcinomaQuality-Adjusted Life YearsNeoplasm Recurrence, LocalAntibodies, Monoclonal, HumanizedHumansUnited StatesGemcitabineMaleFemaleNasopharyngeal NeoplasmsDeoxycytidineCisplatinMiddle AgedAdultCost-Effectiveness Analysis

Stichwörter der Autor:innen

cost effectivenessimmunotherapynasopharyngeal carcinomatoripalimab

Substanzen

Antibodies, Monoclonal, HumanizedGemcitabineDeoxycytidineCisplatintoripalimab

Autor:innen und Institutionen

  • School of Public Health, Fudan University, Shanghai, China.
  • National Health Commission Key Laboratory of Health Technology Assessment, Fudan University, Shanghai, China.
  • School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.

ORCID-Profile: Yi Yang

Zitieren

APA

Lian, D., Gan, Y., Xiao, D., Xuan, D., Chen, Y., & Yang, Y. (2024). Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost‐effectiveness analysis. Cancer Medicine. https://doi.org/10.1002/cam4.7243

Vancouver

Lian D, Gan Y, Xiao D, Xuan D, Chen Y, Yang Y. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost‐effectiveness analysis. Cancer Medicine. 2024. doi:10.1002/cam4.7243

BibTeX
@article{Lian2024,
  author = {Lian, Dai and Gan, Yuling and Xiao, Dunming and Xuan, Dennis and Chen, Yingyao and Yang, Yi},
  title = {Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost‐effectiveness analysis},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7243}
}
Kostenlos starten →